Finance

Lists
Why is NAUT down ३.४०%?
Dive Deeper
NAUT:NASDAQ
Nautilus Biotechnology Inc
US$ २.२७
-३.४०%
(-०.०८०) 1D
नोभेम्बर ४, १२:२९:१६ GMT-५  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NAUT...
Open
US$ २.३२
High
US$ २.३९
Low
US$ २.१५
Mkt. cap
२८.९१ करोड
Avg. vol.
१.०७ करोड
Volume
४४.२१ लाख
52-wk high
US$ ४.३१
52-wk low
US$ ०.८४
EPS
-US$ ०.४६
Beta
०.६६
Shares outstanding
१२.७४ करोड
No. of employees
१२८
Open
US$ २.३२
High
US$ २.३९
Low
US$ २.१५
Mkt. cap
२८.९१ करोड
Avg. vol.
१.०७ करोड
Volume
४४.२१ लाख
52-wk high
US$ ४.३१
52-wk low
US$ ०.८४
EPS
-US$ ०.४६
Beta
०.६६
Shares outstanding
१२.७४ करोड
No. of employees
१२८
News stories
From web sources and news partners
LancasterOnline
LancasterOnline
·
१५ मिनेट पहिले
US stocks surge, and the Dow soars 1,500 points as Brent oil's price drops below $95 per barrel
Yahoo Finance
Yahoo Finance
·
१ घण्टा पहिले
Stocks shrugged off the blue wave overnight — history says don’t trust the bounce yet
ABC News - Breaking News, Latest News and Videos
ABC News - Breaking News, Latest News and Videos
·
२ घण्टा पहिले
Dow surges 1,000 points as Democrats take control of Congress
CNN
CNN
·
३ घण्टा पहिले
Dow jumps by 1,200 points as Democrats take control of Congress
About Nautilus Biotechnology Inc
CEO-
Employees१२८
Founded२०१६
Headquartersसिएटल, वासिङ्टन डी.सी., संयुक्त राज्य अमेरिका
Sector-
Industry-
Websitenautilus.bio
Analyst ratings
Based on 3 analysts giving stock ratings to NAUT in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for NAUT in the last 3 months.
Highest
Current US$ २.२७
US$ ४.०० (+७६.२०%)
Average
US$ ४.०० (+७६.२०%)
Lowest
US$ ४.०० (+७६.२०%)
Analyst
Recommendation
Action
Price target
Projected
Date
Max Masucci
Roth MKM
Buy
Maintained
US$ ४.००
+७६.२%
10/28/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
US$ ४.००
+७६.२%
10/27/2026
Unknown Analyst
Leerink Partners
Buy
Initiated
US$ ४.००
+७६.२%
09/09/2026
Subbu Nambi
Guggenheim
Buy
Reiterated
US$ ४.००
+७६.२%
07/28/2026
Daniel Brennan
TD Cowen
Buy
Maintained
-
-
04/28/2026
Last report
२०२६ अक्टोबर २७
Fiscal period
Q3 2026
-US$ ०.१२ / -US$ ०.१६
+२५.००%beat
Revenue / Est. (USD)
२.३४ लाख / २.०६ लाख
+१३.४५%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
२०२६ सेप्टेम्बर
Revenue
-
-
१.९० लाख
२.३४ लाख
Cost of goods sold
-
-
१५.०० हजार
२४.०० हजार
Cost of revenue
-
-
१५.०० हजार
२४.०० हजार
Research and development expenses
९५.७५ लाख
९७.०७ लाख
९६.१३ लाख
१.०२ करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
५८.४९ लाख
६४.१७ लाख
६३.२५ लाख
६७.७१ लाख
Operating expense
१.५४ करोड
१.६१ करोड
१.५९ करोड
१.६९ करोड
Total operating expenses
१.५४ करोड
१.६१ करोड
१.६० करोड
१.७० करोड
Operating income
-१.५४ करोड
-१.६१ करोड
-१.५८ करोड
-१.६७ करोड
Other non operating income
-१.४५ लाख
-१५.०० हजार
-१३.०० हजार
-७२.०० हजार
EBT including unusual items
-१.३८ करोड
-१.४७ करोड
-१.४५ करोड
-१.५६ करोड
EBT excluding unusual items
-१.३९ करोड
-१.४७ करोड
-१.४५ करोड
-१.५६ करोड
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-१.३८ करोड
-१.४७ करोड
-१.४५ करोड
-१.५६ करोड
Net profit margin
-
-
-७,६१५.२६%
-६,६८२.०५%
Earnings per share
-
-
-
-
Interest and investment income
१६.५४ लाख
१४.४२ लाख
१३.०७ लाख
११.७३ लाख
Interest expense
-
-
-
-
Net interest expenses
१६.५४ लाख
१४.४२ लाख
१३.०७ लाख
११.७३ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-१.५० करोड
-१.५८ करोड
-१.५५ करोड
-१.६५ करोड
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google एपहरू